Glück, Stefan
Regeneron Pharmaceuticals, Inc.,
United States
2025 Rank: 124820
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 4742 out of 355674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 124820 | 134334 |
| Total Cites | 5063 | 5585 |
| H-index | 39 | 40 |
| Hm-index | 16 | 17 |
| Number of Single Authored Papers | 26 | 26 |
| Total Cites to Single Authored Papers | 179 | 191 |
| Number of Single+First Authored Papers | 49 | 49 |
| Total Cites to Single+First Authored Papers | 649 | 721 |
| Number of Single+First+Last Authored Papers | 100 | 100 |
| Total Cites to Single+First+Last Authored Papers | 1850 | 1996 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4790 | 5149 |
| Ratio of Total Citations to Distinct Citing Papers | 1.06 | 1.08 |
| Self-Citation Percentage |
9.35%
|
|
Glück, Stefan
Regeneron Pharmaceuticals, Inc.,
United States
2024 Rank: 121542
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 4667 out of 334837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 121542 | 127461 |
| Total Cites | 4806 | 5349 |
| H-index | 37 | 40 |
| Hm-index | 16 | 17 |
| Number of Single Authored Papers | 26 | 26 |
| Total Cites to Single Authored Papers | 171 | 183 |
| Number of Single+First Authored Papers | 49 | 49 |
| Total Cites to Single+First Authored Papers | 626 | 698 |
| Number of Single+First+Last Authored Papers | 100 | 100 |
| Total Cites to Single+First+Last Authored Papers | 1778 | 1923 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4569 | 4934 |
| Ratio of Total Citations to Distinct Citing Papers | 1.05 | 1.08 |
| Self-Citation Percentage |
10.15%
|
|
Glück, Stefan
Regeneron Pharmaceuticals, Inc.,
United States
2023 Rank: 119267
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 4632 out of 312644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 119267 | 123644 |
| Total Cites | 4579 | 5092 |
| H-index | 36 | 39 |
| Hm-index | 16 | 17 |
| Number of Single Authored Papers | 26 | 26 |
| Total Cites to Single Authored Papers | 162 | 174 |
| Number of Single+First Authored Papers | 49 | 49 |
| Total Cites to Single+First Authored Papers | 606 | 678 |
| Number of Single+First+Last Authored Papers | 100 | 100 |
| Total Cites to Single+First+Last Authored Papers | 1699 | 1843 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4359 | 4716 |
| Ratio of Total Citations to Distinct Citing Papers | 1.05 | 1.08 |
| Self-Citation Percentage |
10.07%
|
|
Glück, Stefan
Sylvester Comprehensive Cancer Center,
United States
2022 Rank: 114538
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 4444 out of 293195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 114538 | 118623 |
| Total Cites | 4288 | 4769 |
| H-index | 35 | 37 |
| Hm-index | 15 | 17 |
| Number of Single Authored Papers | 26 | 26 |
| Total Cites to Single Authored Papers | 156 | 168 |
| Number of Single+First Authored Papers | 49 | 49 |
| Total Cites to Single+First Authored Papers | 576 | 647 |
| Number of Single+First+Last Authored Papers | 100 | 100 |
| Total Cites to Single+First+Last Authored Papers | 1613 | 1755 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4102 | 4440 |
| Ratio of Total Citations to Distinct Citing Papers | 1.05 | 1.07 |
| Self-Citation Percentage |
10.09%
|
|
Glück, Stefan
Regeneron Pharmaceuticals, Inc.,
United States
2021 Rank: 111758
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 4371 out of 271773 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 111758 | 116300 |
| Total Cites | 4126 | 4594 |
| H-index | 34 | 36 |
| Hm-index | 15 | 16 |
| Number of Single Authored Papers | 26 | 26 |
| Total Cites to Single Authored Papers | 156 | 168 |
| Number of Single+First Authored Papers | 49 | 49 |
| Total Cites to Single+First Authored Papers | 553 | 623 |
| Number of Single+First+Last Authored Papers | 101 | 101 |
| Total Cites to Single+First+Last Authored Papers | 1556 | 1696 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3949 | 4278 |
| Ratio of Total Citations to Distinct Citing Papers | 1.04 | 1.07 |
| Self-Citation Percentage |
10.19%
|
|
Glück, Stefan
Celgene Corporation,
United States
2020 Rank: 108278
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 4394 out of 230678 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 108278 | 112757 |
| Total Cites | 3754 | 4214 |
| H-index | 32 | 34 |
| Hm-index | 15 | 16 |
| Number of Single Authored Papers | 27 | 27 |
| Total Cites to Single Authored Papers | 155 | 168 |
| Number of Single+First Authored Papers | 50 | 50 |
| Total Cites to Single+First Authored Papers | 504 | 579 |
| Number of Single+First+Last Authored Papers | 104 | 104 |
| Total Cites to Single+First+Last Authored Papers | 1425 | 1573 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3618 | 3942 |
| Ratio of Total Citations to Distinct Citing Papers | 1.04 | 1.07 |
| Self-Citation Percentage |
10.92%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.